Patents by Inventor Jayaprakash K. Nair

Jayaprakash K. Nair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENDOSOMAL CLEAVABLE LINKERS
    Publication number: 20220177885
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Application
    Filed: February 10, 2022
    Publication date: June 9, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher S. THEILE, Martin MAIER, Ivan ZLATEV
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    Publication number: 20220143189
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 12, 2022
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Martin MAIER
  • EXTRAHEPATIC DELIVERY
    Publication number: 20220125823
    Abstract: The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier.
    Type: Application
    Filed: May 7, 2019
    Publication date: April 28, 2022
    Inventors: Jayaprakash K. NAIR, Martin MAIER, Vasant JADHAV, Stuart MILSTEIN, Kirk BROWN, Rubina G. PARMAR, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Alexander V. KEL'IN, Muthusamy JAYARAMAN, Klaus CHARISSE, Adam CASTORENO, Christopher S. THEILE, Kevin FITZGERALD
  • MULTI-TARGETED SINGLE ENTITY CONJUGATES
    Publication number: 20220106593
    Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.
    Type: Application
    Filed: February 22, 2021
    Publication date: April 7, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant JADHAV, Martin MAIER, Ivan ZLATEV, Akin AKINC, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Pachamuthu KANDASAMY, Muthiah MANOHARAN
  • Endosomal cleavable linkers
    Patent number: 11286482
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: March 29, 2022
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. Nair, Kallanthottathil G. Rajeev, Scott Lentini, Christopher S. Theile, Martin Maier, Ivan Zlatev
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    Publication number: 20220008541
    Abstract: The present invention provides a phosphorothioate-modified oligonucleotide comprising a structure shown below: The present invention also provides a phosphorothioate-modified oligonucleotide comprising a structure having formula (CIII):
    Type: Application
    Filed: July 6, 2021
    Publication date: January 13, 2022
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jayaprakash K. NAIR, Martin MAIER
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210269796
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 2, 2021
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
    Publication number: 20210238595
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2?-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: May 16, 2019
    Publication date: August 5, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Shigeo MATSUDA, Mark K. SCHLEGEL, Maja JANAS, Vasant R. JADHAV, Martin MAIER, Klaus CHARISSE, Muthiah MANOHARAN, Kallathotathil G. RAJEEV, Jayaprakash K. NAIR
  • CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS
    Publication number: 20210207144
    Abstract: The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 8, 2021
    Inventors: Muthiah MANOHARAN, Nate TANEJA, Hartmut Ingo JAHNS, Shigeo MATSUDA, Klaus CHARISSE, Guo HE, Jayaprakash K. NAIR, Christopher BROWN, Mark K. SCHLEGEL, Vasant JADHAV, Martin MAIER
  • Multi-targeted single entity conjugates
    Patent number: 11053495
    Abstract: The present invention relates, in general to, compounds, compositions and methods useful for modulating gene expression of multiple target nucleic acids by a single chemical entity.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 6, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Vasant Jadhav, Martin Maier, Ivan Zlatev, Akin Akinc, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Pachamuthu Kandasamy, Muthiah Manoharan
  • NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
    Publication number: 20210162053
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Application
    Filed: October 7, 2020
    Publication date: June 3, 2021
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10995336
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 4, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS
    Publication number: 20210087219
    Abstract: This invention relates to an oligonucleotide comprising one or more abasic nucleoside monomers of formula IV?: These monomers are useful for modifying of oligonucleotides at one or more positions. This invention also relates to a method of inhibiting the expression of a target gene in a cell. The method comprises contacting the cell with an oligonucleotide having one or more of the above formula (IV?).
    Type: Application
    Filed: December 3, 2020
    Publication date: March 25, 2021
    Inventors: Muthiah MANOHARAN, Kallanthottathil G. RAJEEV, Jeremy LACKEY, Jayaprakash K. NAIR
  • LIPID CONTAINING FORMULATIONS
    Publication number: 20200361854
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 19, 2020
    Applicant: Arbutus Biopharma Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
  • Lipids and compositions for the delivery of therapeutics
    Patent number: 10835612
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: November 17, 2020
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Butler, Jayaprakash K. Nair, Muthusamy Jayaraman, Laxman Eltepu
  • Lipids and compositions for the delivery of therapeutics
    Patent number: 10821186
    Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: November 3, 2020
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Jayaprakash K. Nair, Martin Maier, Laxman Eltepu
  • Oligonucleotide-ligand conjugates and process for their preparation
    Patent number: 10808246
    Abstract: The present invention relates to ligand conjugates of iRNA agents (such as siRNA) of the formula
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: October 20, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Jayaprakash K. Nair, Pachamuthu Kandasamy, Shigeo Matsuda, Alexander V. Kelin, Muthusamy Jayaraman, Kallanthottathil G. Rajeev
  • Monomers and oligonucleotides comprising cycloaddition adduct(s)
    Patent number: 10550386
    Abstract: The invention features compounds of formula V or XII: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: February 4, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Jayaprakash K. Nair, Kallanthottahil G. Rajeev, Michael E. Jung
  • ENDOSOMAL CLEAVABLE LINKERS
    Publication number: 20190330630
    Abstract: The present disclosure relates generally to cleavable linkers and uses thereof.
    Type: Application
    Filed: January 18, 2018
    Publication date: October 31, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. NAIR, Kallanthottathil G. RAJEEV, Scott LENTINI, Christopher THEILE, Martin MAIER, Ivan ZLATEV
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190316127
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: May 23, 2019
    Publication date: October 17, 2019
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein